Related Experiment Videos
Ribavirin treatment for chronic hepatitis D: a pilot study
A Garripoli1, V Di Marco, R Cozzolongo
1Department of Gastroenterology, Molinette Hospital, Torino, Italy.
Liver
|June 1, 1994
Summary
Ribavirin therapy did not demonstrate significant antiviral effects for chronic hepatitis D. The drug was ineffective in reducing viral load or biochemical markers of liver inflammation and necrosis in patients.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis D is a severe liver disease caused by the hepatitis D virus (HDV).
- Current treatment options for chronic hepatitis D are limited, necessitating research into novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of Ribavirin in treating chronic hepatitis D.
- To assess Ribavirin's impact on HDV viremia and liver inflammation markers.
Main Methods:
- Nine Italian patients with chronic hepatitis D received oral Ribavirin (15 mg/kg daily) for 16 weeks.
- Patients were monitored for HDV viremia and alanine transferase (ALT) levels post-treatment for 12 months.
Main Results:
- Ribavirin showed minimal impact on HDV viremia; reduction occurred in two patients, while five showed no change.
- No significant decrease in ALT levels (by more than 50%) was observed in any patient.
- Two patients discontinued treatment due to adverse events: hemolytic anemia and intractable itching.
Conclusions:
- Ribavirin, at the studied dosage, did not exhibit significant antiviral activity against chronic hepatitis D.
- The drug was ineffective in reducing biochemical markers of liver inflammation and necrosis in this patient cohort.
- Further research is needed to identify effective treatments for chronic hepatitis D.